We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Who we are

Galapagos (Euronext & NASDAQ: GLPG) is a commercial-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1 studies, pre-clinical studies and discovery programs in inflammation, fibrosis, and other indications. 

We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people’s lives.

Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease rather than just treating the symptoms. Galapagos’ aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.

Galapagos has more than 1,200 employees worldwide, with sites in Belgium (international headquarters), the Netherlands, France, Germany, Italy, Spain, Switzerland, the UK and the US.

In 2019, Galapagos entered into a transformative 10-year global research and development collaboration with Gilead. The collaboration will allow for closer scientific partnership between the companies.